Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in lewy body disease

Journal of Alzheimer's Disease

Volumn 22, Issue 3, 2010, Pages 933-938

  Maetzler, Walter ^a,b   Stoycheva, Velichka ^a   Schmid, Benjamin ^a   Schulte, Claudia ^a   Hauser, Ann Kathrin ^a   Brockmann, Kathrin ^a   Melms, Arthur ^c   Gasser, Thomas ^a   Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alzheimer's disease; enzyme; Lewy body disease; metalloendopeptidase; Parkinson's disease; spinal puncture

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; MEMBRANE METALLOENDOPEPTIDASE; TAU PROTEIN;

AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SIGNAL TRANSDUCTION;

EID: 78650656088     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101197     Document Type: Article

References (27)

1. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosa- ka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nuss- baum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812-819.
2. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha- synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152, 879-884.
3. Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 8, 1158-1171.
4. Jellinger KA, Seppi K, Wenning GK (2003) Clinical and neu- ropathological correlates of Lewy body disease. Acta Neu- ropathol 106, 188-189; author reply 190.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211.
6. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34, 107-112.
7. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79, 1331-1338.
8. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
9. Howell S, Nalbantoglu J, Crine P (1995) Neutral endopepti- dase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16, 647-652.
10. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 15501552.
11. Spillantini MG, Sicuteri F, Salmon S, Malfroy B (1990) Characterization of endopeptidase 3.4.24.11 ("enkephalinase") activity in human plasma and cerebrospinal fluid. Biochem Pharmacol 39, 1353-1356.
12. Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL (2001) Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res 902, 277-281.
13. Yasojima K, Akiyama H, McGeer EG, McGeer PL (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 297, 97-100.
14. Newell AJ, Sue LI, Scott S, Rauschkolb PK, Walker DG, Potter PE, Beach TG (2003) Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. NeurosciLett 350, 178-180.
15. Hellstrom-Lindahl E, Ravid R, Nordberg A (2008) Age- dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging 29, 210-221.
16. Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M, Tomita N, Matsui T, Iwata N, Mizukami H, Mura- matsu S, Ozawa K, Saido TC, Arai H, Sasaki H (2005) Cere- brospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 57, 832-842.
17. Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 38, 1402-1406.
18. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feld- man H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.
19. Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, Huber H, Brockmann K, Gasser T, Berg D, Melms A (2010) The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 19, 937-942.
20. Spillantini MG, Geppetti P, Fanciullacci M, Michelacci S, Lecomte JM, Sicuteri F (1986) In vivo 'enkephalinase' inhibition by acetorphan in human plasma and CSF. Eur J Pharmacol 125, 147-150.
21. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548.
22. Hersh LB, Rodgers DW (2008) Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 5, 225-231.
23. Cummings JL (1988) Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1, 24-36.
24. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60, 387-392.
25. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681-693.
26. Llorens-Cortes C, Javoy-Agid F, Agid Y, Taquet H, Schwartz JC (1984) Enkephalinergic markers in substantia nigra and caudate nucleus from Parkinsonian subjects. JNeurochem 43, 874-877.
27. Shipp MA, Richardson NE, Sayre PH, Brown NR, Mas- teller EL, Clayton LK, Ritz J, Reinherz EL (1988) Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci USA 85, 4819-4823.